Characteristics of studies included in the metaanalysis.
| Study | Yr | LEF, n | Comparator, n | Study Duration, Weeks | Age, Yrs* | Female, % | Disease Duration, Yrs* | LEF-naive, % | Comparator Drug |
|---|---|---|---|---|---|---|---|---|---|
| Chen, et al20 | 2013 | 886 | 898 | 52 | NA | NA | NA | NA | PAE + CCPI |
| Jaimes-Hernandez, et al21 | 2012 | 43 | 42 | 52 | 43 | 87 | 2 | 98 | MTX |
| Ishaq, et al22 | 2011 | 91 | 89 | 52 | 58 | 71 | 4 | NA | MTX |
| Kremer, et al23 | 2002 | 130 | 133 | 24 | 56 | 78 | 11 | 100 | PBO |
| Cohen, et al24 | 2001 | 190 | 318 | 104 | 54 | 73 | 7 | NA | MTX/PBO |
| Emery, et al25 | 2000 | 501 | 498 | 104 | 58 | 71 | 4 | NA | MTX |
| Smolen, et al26 | 1999 | 133 | 225 | 24 | 59 | 73 | 7 | 100 | SSZ/PBO |
| Mladenovic, et al27 | 1995 | 300 | 102 | 24 | 51 | 83 | 8 | 100 | PBO |
↵* Age and duration of disease expressed as mean as reported by individual studies. LEF: leflunomide; NA: not available; PAE: paeoniflorin; CCPI: cervus and cucumis polypeptide injection; MTX: methotrexate; SSZ: sulfasalazine; PBO: placebo.